ELTX

Elicio Therapeutics, Inc.

Investor Moves

NameValueActionChangePriceLast Price
Ken GriffinCitadel Advisors
$835k78.1k shares
AddQ1 2026
$408k
$10.69
$3.11
Steven CohenPoint72
$-92.8K
ExitQ1 2026
$93k
--
$3.11
Jim SimonsRenaissance Technologies
$1M121.6k shares
AddQ1 2026
$1M
$10.69
$3.11
Jefferies GroupInvestor
$-95.1K
ExitQ1 2026
$95k
--
$3.11
Ken GriffinCitadel Advisors
$196.9K
AddQ4 2025
$197k
--
$3.11
Jim SimonsRenaissance Technologies
$-308.7K
TrimQ4 2025
$309k
--
$3.11

Insider Trades

NameValueActionPriceLast Price
Chudnovsky YekaterinaDirector, 10 Percent Owner:
$20M3.4M shares
BuyAug 12, 2024
$5.81
$3.11

News

benzinga.comElicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drugbenzinga.comJun 17globenewswire.comElicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancerglobenewswire.comJun 17prnewswire.comElicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)prnewswire.comJun 16benzinga.comElicio Therapeutics Pancreatic Cancer Study Disappointsbenzinga.comJun 15globenewswire.comELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.globenewswire.comJun 15